Novartis AG(NOT.DE)

Last Updated 00:00:00
longbridge loading

Thrive Capital, Alphabet To Lead Isomorphic Labs $2 Billion Fundraising Goal

benzinga_article·
US
JNJ
+0.47%
US
LLY
+3.37%
US
GOOG
-2.09%
benzinga_article·
US
JNJ
+0.47%
US
LLY
+3.37%
US
GOOG
-2.09%

Kepler Capital Remains a Buy on Novartis AG (NOVN)

Tip Ranks·
DE
NOT
0.00%
US
NVS
+0.86%
US
FBT
+0.54%
Tip Ranks·
DE
NOT
0.00%
US
NVS
+0.86%
US
FBT
+0.54%

Construction begins on Novartis’ RLT centre in Texas, US

Pharmaceutical Technology·
US
NVS
+0.86%
DE
NOT
0.00%
US
IXJ
+0.79%
Pharmaceutical Technology·
US
NVS
+0.86%
DE
NOT
0.00%
US
IXJ
+0.79%

Key facts: Novartis wins EU OK for Rhapsido; builds Morrisville API site

TradingView·
DE
NOT
0.00%
US
NVS
+0.86%
US
IBB
+0.10%
TradingView·
DE
NOT
0.00%
US
NVS
+0.86%
US
IBB
+0.10%

Assessing Novartis (SWX:NOVN) Valuation After Recent Share Weakness And Long Term Gains

Simplywall·
US
NVS
+0.86%
DE
NOT
0.00%
US
XLV
+1.10%
Simplywall·
US
NVS
+0.86%
DE
NOT
0.00%
US
XLV
+1.10%

Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA

rttnews·
DE
NOT
0.00%
US
NVS
+0.86%
UK
AZN
0.00%
rttnews·
DE
NOT
0.00%
US
NVS
+0.86%
UK
AZN
0.00%

Deutsche Bank Sticks to Their Buy Rating for Novartis AG (NOVN)

Tip Ranks·
DE
NOT
0.00%
US
NVS
+0.86%
Tip Ranks·
DE
NOT
0.00%
US
NVS
+0.86%

Novartis (NVS) CEO Warns Trump Drug Pricing Policy Could Hit Global Access as Earnings Slip

Tip Ranks·
DE
NOT
0.00%
US
NVS
+0.86%
US
FBT
+0.54%
Tip Ranks·
DE
NOT
0.00%
US
NVS
+0.86%
US
FBT
+0.54%
© 2026 Longbridge｜Disclaimer